Literature DB >> 25431235

Nuclear expression and gain-of-function β-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker.

Jerzy Lasota1, Anna Felisiak-Golabek1, F Zahra Aly2, Zeng-Feng Wang1, Lester D R Thompson3, Markku Miettinen1.   

Abstract

Glomangiopericytoma (sinonasal-type hemangiopericytoma) is a rare mesenchymal neoplasm with myoid phenotype (smooth muscle actin-positive), which distinguishes this tumor from soft tissue hemangiopericytoma/solitary fibrous tumor. Molecular genetic changes underlying the pathogenesis of glomangiopericytoma are not known. In this study, 13 well-characterized glomangiopericytomas were immunohistochemically evaluated for β-catenin expression. All analyzed tumors showed strong expression and nuclear accumulation of β-catenin. Following this observation, β-catenin glycogen serine kinase-3 beta phosphorylation region, encoded by exon 3, was PCR amplified in all cases and evaluated for mutations using Sanger sequencing. Heterozygous mutations were identified in 12 of 13 tumors. All mutations consisted of single-nucleotide substitutions: three in codon 32 (c.94G>C (n=2) and c.95A>T), four in codon 33 (two each c.98C>G and c.98C>T), two in codon 37 (c.109T>G), one in codon 41 (c.121A>G), and two in codon 45 (c.133T>C). At the protein level, these substitutions would lead to p.D32H, p.D32V, p.S33C, p.S33F, p.S37A, p.T41A, and p.S45L mutations, respectively. Previously, similar mutations have been reported in different types of cancers and shown to trigger activation of β-catenin signaling. All analyzed glomangiopericytomas showed prominent nuclear expression of cyclin D1, as previously shown for tumors with nuclear expression of β-catenin as a sign of oncogenic activation. These results demonstrate that mutational activation of β-catenin and associated cyclin D1 overexpression may be central events in the pathogenesis of glomangiopericytoma. In additon, nuclear accumulation of β-catenin is a diagnostic marker for glomangiopericytoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25431235      PMCID: PMC7712456          DOI: 10.1038/modpathol.2014.161

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Novel MIR143-NOTCH fusions in benign and malignant glomus tumors.

Authors:  Juan-Miguel Mosquera; Andrea Sboner; Lei Zhang; Chun-Liang Chen; Yun-Shao Sung; Hsiao-Wei Chen; Narasimhan P Agaram; Daniel Briskin; Basma M Basha; Samuel Singer; Mark A Rubin; Thomas Tuschl; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2013-09-02       Impact factor: 5.006

2.  Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3.

Authors:  Y Miyoshi; K Iwao; Y Nagasawa; T Aihara; Y Sasaki; S Imaoka; M Murata; T Shimano; Y Nakamura
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

3.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

Authors:  H Takayasu; H Horie; E Hiyama; T Matsunaga; Y Hayashi; Y Watanabe; S Suita; M Kaneko; F Sasaki; K Hashizume; T Ozaki; K Furuuchi; M Tada; N Ohnuma; A Nakagawara
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

5.  Immunohistochemical expression of beta-catenin in solitary fibrous tumors.

Authors:  Dinesh Rakheja; Kyle H Molberg; Cory A Roberts; Vilkesh R Jaiswal
Journal:  Arch Pathol Lab Med       Date:  2005-06       Impact factor: 5.534

6.  Hemangiopericytoma-like intranasal tumors. A clinicopathologic study of 23 cases.

Authors:  J Compagno; V J Hyams
Journal:  Am J Clin Pathol       Date:  1976-10       Impact factor: 2.493

7.  Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells.

Authors:  Makoto Saegusa; Miki Hashimura; Takeshi Kuwata; Mieko Hamano; Isao Okayasu
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.

Authors:  Colleen H Anna; Mari Iida; Robert C Sills; Theodora R Devereux
Journal:  Toxicol Appl Pharmacol       Date:  2003-07-15       Impact factor: 4.219

9.  Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis.

Authors:  Umio Yamaguchi; Tadashi Hasegawa; Taizo Masuda; Shigeki Sekine; Akira Kawai; Hirokazu Chuman; Tadakazu Shimoda
Journal:  Virchows Arch       Date:  2004-06-30       Impact factor: 4.064

10.  Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.

Authors:  Juliann Chmielecki; Aimee M Crago; Mara Rosenberg; Rachael O'Connor; Sarah R Walker; Lauren Ambrogio; Daniel Auclair; Aaron McKenna; Michael C Heinrich; David A Frank; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-01-13       Impact factor: 38.330

View more
  26 in total

1.  Endoscopic resection of invasive glomangiopericytoma following preoperative embolisation.

Authors:  Vitor Manuel Oliveira; Gonçalo Neto Almeida; Deodato Rego Silva; Pedro Alberto Escada
Journal:  BMJ Case Rep       Date:  2016-02-17

2.  Orbit Solitary Fibrous Tumor: A Proposed Risk Prediction Model Based on a Case Series and Comprehensive Literature Review.

Authors:  Lester D R Thompson; Sofia S Liou; Kenneth A Feldman
Journal:  Head Neck Pathol       Date:  2020-06-11

3.  β-catenin (CTNNB1) mutation and LEF1 expression in sinonasal glomangiopericytoma (sinonasal-type hemangiopericytoma).

Authors:  Yuka Suzuki; Shu Ichihara; Tomonori Kawasaki; Hiroyuki Yanai; Satoshi Kitagawa; Yoshie Shimoyama; Shigeo Nakamura; Masato Nakaguro
Journal:  Virchows Arch       Date:  2018-05-07       Impact factor: 4.064

Review 4.  Angioleiomyoma of the Sinonasal Tract: Analysis of 16 Cases and Review of the Literature.

Authors:  Abbas Agaimy; Michael Michal; Lester D R Thompson; Michal Michal
Journal:  Head Neck Pathol       Date:  2015-06-06

Review 5.  Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity.

Authors:  Simon Andreasen; Justin A Bishop; Henrik Hellquist; Jennifer Hunt; Katalin Kiss; Alessandra Rinaldo; Alena Skálová; Stefan M Willems; Michelle Williams; Alfio Ferlito
Journal:  Virchows Arch       Date:  2018-08-14       Impact factor: 4.064

Review 6.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.

Authors:  Lester D R Thompson; Alessandro Franchi
Journal:  Virchows Arch       Date:  2017-04-25       Impact factor: 4.064

7.  Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics.

Authors:  Vickie Y Jo; Christopher D M Fletcher
Journal:  Head Neck Pathol       Date:  2016-06-20

8.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Edward B Stelow; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2017-02-28

Review 9.  [Sinonasal tumors : News from the WHO with special reference to mesenchymal entities].

Authors:  A Agaimy; F Haller; A Hartmann
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

10.  Colon cancers carrying BRAF V600E and β-catenin T41A activating mutations are resistant to numerous common anticancer drugs.

Authors:  Guangzhong Xu; Kai Li; Nengwei Zhang; Bin Zhu; Guosheng Feng; Qing Fan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.